Clinical trial
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Anti-minor Histocompatibility Complex (MiHA) Donor T-lymphocytes Expanded ex Vivo, in Patients With a Hematologic Malignancy, With Molecular or Clinical Relapse After Hematopoietic Stem Cell Transplantation From a Matched Donor
NCT03091933 is registered in ClinicalTrials.gov with Ciusss de L'Est de l'Île de Montréal as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Anti-minor Histocompatibility Complex (MiHA) Donor T-lymphocytes Expanded ex Vivo, in Patients With a Hematologic Malignancy, With Molecular or Clinical Relapse After Hematopoietic Stem Cell Transplantation From a Matched Donor
- Lead sponsor
- Ciusss de L'Est de l'Île de Montréal
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- February 6, 2017
- Completion date
- March 31, 2019
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hematologic cancer, relapse leukemia, relapsed adult all, relapsed adult aml, relapsed cll, relapsed hodgkin's lymphoma, relapsed multiple myeloma, relapsed myelodysplastic syndromes, relapsed non hodgkin lymphoma